Advertisement

Topics

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% | Olopatadine Hydrochloride [Cipla USA Inc.] | BioPortfolio

13:33 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H-receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88. The chemical structure is presented below:

Chemical Name: 11-[(Z)-3-(Dimethylamino) propylidene] -6-11-dihydrodibenz [b, e] oxepin-2-acetic acid hydrochloride

Each mL of Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% contains: Active: 1.11 mg olopatadine hydrochloride equivalent to 1 mg olopatadine.

Preservative: benzalkonium chloride 0.01 %. Inactives: dibasic sodium phosphate; sodium chloride; hydrochloric acid/sodium hydroxide (adjust pH); and water for injection. It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.

Results from an environmental study demonstrated that Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% was effective in the treatment of the signs and symptoms of allergic conjunctivitis when dosed twice daily for up to 6 weeks. Results from conjunctival antigen challenge studies demonstrated that Olopatadine Hydrochloride Ophthalmic Solution USP 0.1%, when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components of Olopatadine Hydrochloride Ophthalmic Solution USP 0.1%.

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% is for topical use only and not for injection or oral use.

To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

Patients should be advised not to wear a contact lens if their eye is red. Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% should not be used to treat contact lens related irritation. The preservative in Olopatadine Hydrochloride Ophthalmic Solution USP 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% before they insert their contact lenses.

Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 microliter drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7,800 times the maximum recommended ocular human use level.

Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% is administered to a nursing mother.

Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Headaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritis, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% is supplied as follows: 5 mL in white opaque low density polyethylene bottle with translucent low density polyethylene dropper and white opaque high density polyethylene cap.

5 mL: NDC 69097-275-35

Storage: Store between 4°C-25°C (39°F-77°F), Protect from light.

Rx Only

Manufactured by:

Cipla Ltd.

Plot 9 & 10, Indore SEZ,

Pithampur, M.P.-454 775,

INDIA

Manufactured for:

Cipla USA, Inc.,

1560, Sawgrass, Suite 130,

Sunrise, FL, 33323

Revised Date: 04/ 2018

NDC 69097-275-35

0.1%

Olopatadine

Hydrochloride

Ophthalmic Solution, USP

0.1%

Rx ONLY

NDC 69097-275-35  Rx only

Olopatadine Hydrochloride

Ophthalmic

Solution, USP

0.1%

For Topical Application

In the Eye

5ml

Cipla

Manufacturer

Cipla USA Inc.

Active Ingredients

Source

Drugs and Medications [223 Associated Drugs and Medications listed on BioPortfolio]

Olopatadine hydrochloride [apotex corp.]

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

Olopatadine hydrochloride [preferred pharmaceuticals inc.]

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

Olopatadine hydrochloride [a-s medication solutions]

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

Olopatadine hydrochloride [aurobindo pharma limited]

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% Rx Only

Olopatadine [golden state medical supply, inc]

Olopatadine

Clinical Trials [2212 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to les...

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% & Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergi...

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.

Mast-Cell Stabilizing Effects of Olopatadine

To assess the effects of olopatadine of the release of mast cell histamine

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunct...

PubMed Articles [207 Associated PubMed Articles listed on BioPortfolio]

Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in an Environmental Exposure Chamber Study.

GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate intended for seasonal allergic rhinitis (SAR) treatment.

Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats.

Berberine hydrochloride is one the effective compound among Rhizoma Coptidis, Cortex Phellodendri, and other plants. There are several clinical functions of berberine hydrochloride including anti-infl...

In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.

A number of drug-releasing contact lenses are currently being studied to address issues inherent in eye drops as a drug delivery method. In this study, we developed epinastine hydrochloride-releasing ...

In vitro and ex vivo studies on Diltiazem hydrochloride-loaded microsponges in rectal gels for chronic anal fissures treatment.

Diltiazem hydrochloride, topically applied at 2% concentration, is considered effective for the treatment of chronic anal fissures, althought it involves several side effects among which anal pruritus...

Tramadol hydrochloride: An alternative to conventional local anaesthetics for intraoral procedures- a preliminary study.

To evaluate and compare the soft tissue anaesthesia produced by tramadol hydrochloride on gingival tissues in maxilla.

Advertisement
Quick Search
Advertisement
Advertisement

 

Drugs and Medication Quicklinks


Searches Linking to this Drug Record